The contract is part of the U.S. government’s effort to double its procurement of rapid COVID-19 tests to be delivered for free to Americans through a forthcoming federal website.
Read More
Matthew Sause took the helm of the 4,500-person Roche Diagnostics’ North American operations in Indianapolis in November 2019—just four months before the World Health Organization declared a pandemic and much of the planet went into lockdown.
Crystal Derrick, who was a national account manager in Roche’s diabetes division, had accused the company of illegally paying insurance company Humana Inc. for access to certain formularies.
Roche Diagnostics’ North American headquarters in Indianapolis will be the shipping and distribution hub for all tests distributed in the United States, the company said.
Indianapolis-based Roche Diagnostics said Monday that it has begun shipping an initial order of 400,000 COVID-19 test kits to a network of more than 30 hospital and laboratories.
Spark Therapeutics Inc. will give Roche Holding a chance to make up ground in a field where single treatments may command more than $1 million. It also snaps up an asset that rivals like Novartis might have coveted.
Castleton remains central Indiana’s most expansive retail corridor, but does its retail focus—and its car-centric layout—suggest trouble lies ahead?
The company, which employs more than 3,000 on the northeast side, has been struggling on the diabetes side of its business. To bounce back, it is investing heavily in diagnostics, and is working to commercialize several products it hopes will be game-changers.
The “Roche Academy” will provide mentors, internships and special curriculum to biology and chemistry undergrads, along with financial incentives and a job offer after graduation.
Roche Holding AG—the Basel, Switzerland-based parent of Indianapolis-based Roche Diagnostics—has enlisted a little green gremlin to help rescue its diabetes business after a decade of declining sales.
Roche Group is rolling out a new blood-glucose meter and a savings program for test strips, which it says it will make diabetes care more affordable.
Two Indianapolis-based subsidiaries of Swiss pharmaceutical giant Roche Group are accusing a group of pharmacies and supply houses of engaging in an elaborate scheme to defraud Roche of millions of dollars worth of sales on diabetes test strips.
The Swiss-based company confirmed Wednesday morning the cuts are part of a U.S. restructuring that will result in eliminating 133 full-time workers and 24 contractors.
Since 2012, the company has built five buildings, refurbished existing buildings, made upgrades to IT infrastructure, and increased investments in its diabetes care manufacturing technology.
A Census Bureau survey suggests that medical device firms created 20,000 fewer jobs from 2011 to 2013 than they should have—and some of those missing jobs probably can be blamed on Obamacare’s medical device tax.
Indiana's life sciences companies are spending four times more on medical research than the state's hospitals, doctors and univerities are receiving from such companies for research projects. That means Indiana is missing out on more than $80 million a year.
New research shows patients lose trust and confidence in doctors that take money for travel, but like it when their doctors are paid as consultants during the development of new products.
The future of U.S. health care will be about precision and parsimony. And Roche Diagnostics Corp. think its new line of DNA-level testing machines are just what the doctor ordered.
New tests have helped Roche Diagnostics grow its North American revenue, excluding its troubled diabetes care business, 23 percent over the past five years. But the money for diagnostic tests continues to go down in key areas, noted CFO Wayne Burris.
While life sciences companies don’t rack up huge jobs numbers, their relatively high pay means that every job they create is worth two in the rest of the private sector.
U.S. sales are plunging for Roche Diagnostics Corp. and its fellow makers of diabetes-care devices because of lower reimbursements from the federal Medicare program. In five years, two of the four largest companies will have sold or closed their diabetes businesses, according to two industry analysts.
